News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celltrion, Inc. (068270.KQ) Files For Approval Of Remicade Biosimilar In US



8/13/2014 12:34:01 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Celltrion, a Korean biotech, filed with the FDA for approval of Remsima®, a biosimilar to Janssen’s Remicade, which is indicated for autoimmune diseases. Remsima is the first monoclonal antibody to seek approval in the US under the 351(k) rules for biosimilars. In 2009, Celltrion and Hospira agreed to become co-exclusive distributors of Remsima as part of a package of eight biosimilars (now expanded to eleven) under development at Celltrion. More details....

Stock Symbols: (KOSDAQ: 068270) (NYSE: HSP)

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES